Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes | Zendy

Edmund J. Lewis | Zendy; Lawrence G. Hunsicker | Zendy; William R. Clarke | Zendy; Tomás Berl | Zendy; Marc A. Pohl | Zendy; Julia B. Lewis | Zendy; Eberhard Ritz | Zendy; Robert C. Atkins | Zendy; Richard Rohde | Zendy; Itamar Raz | Zendy

Open Access

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Author(s) -

Edmund J. Lewis,

Lawrence G. Hunsicker,

William R. Clarke,

Tomás Berl,

Marc A. Pohl,

Julia B. Lewis,

Eberhard Ritz,

Robert C. Atkins,

Richard Rohde,

Itamar Raz

Publication year - 2001

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa011303

Subject(s) - irbesartan , amlodipine , medicine , diabetic nephropathy , creatinine , type 2 diabetes , blood pressure , endocrinology , angiotensin ii receptor antagonist , urology , placebo , kidney disease , diabetes mellitus , nephropathy , angiotensin ii , angiotensin receptor , pathology , alternative medicine

It is unknown whether either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression of nephropathy in patients with type 2 diabetes independently of its capacity to lower the systemic blood pressure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research